Cystatin-C as a predictor for major adverse cardiac events in patients with acute coronary syndrome

Egyptian Heart Journal

Volumn 64, Issue 3, 2012, Pages 87-95

  Tayeh, Osama ^a   Rizk, Amal ^a   Mowafy, Ahmed ^a   Salah, Sally ^a   Gabr, Khald ^a  

^a Cairo University   (Egypt)

Author keywords

Acute coronary syndrome; Cystatin C; Major adverse cardiac events

Indexed keywords

CYSTATIN C; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CIGARETTE SMOKING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DISEASE; HEART FAILURE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SERUM; SURVIVAL RATE; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 84879194089     PISSN: 11102608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2012.03.002     Document Type: Article

References (37)

1. Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function-measured and estimated - glomerular filtration rate. N Engl J Med 2006, 354:2473-2483.
2. Liu J., Sukhova G.K., Sun J.S., Xu W.H., Libby P., Shi G.P. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:1359-1366.
3. Shlipak M.G., Katz R., Sarnak M.J. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006, 145:237-246.
4. Shlipak M.G., Sarnak M.J., Katz R. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352:2049-2060.
5. Smith G.L., Lichtman J.H., Bracken M. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47:1987-1996.
6. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovasucular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2005, 108:2154-2169.
7. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004, 110:2342-2348.
8. Keller T., Messow C.M., Lubos E. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 2009, 30:314-320.
9. Thygesen K., Alpert J.S., White H.D. Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538.
10. Apple F.S., Murakami M.M. Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction. Clin Chem 2005, 51:460-463.
11. Westgard JO, Klee GG. Quality management. In: Burtis CA, Ashwood ER, Bruns DE, editors. Textbook of clinical chemistry and molecular diagnostics, 4th ed. St. Louis, MO: Elsevier Saunders; 2006. p. 498-9.
12. Kushner F.G., Hand M., Smith S.C. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241.
13. Anderson J.L., Adams C.D., Antman E.M. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007, 50:1-157.
14. Jacobs D.R., Kroenke C., Crow R., Deshpande M., Gu D.F., Gatewood L., et al. PREDICT. A simple risk score for clinical severity and long-term prognosis after hospitalisation for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation 1999, 100:599-607.
15. Selvin E., Manzi J., Stevens L.A., Van Lente F., Lacher D.A., Levey A.S. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis 2007, 50:918-926.
16. Uhlmann E.J., Hock K.G., Issitt C. Reference intervals for plasma cystatin C in healthy volunteers and renal patients, as measured by the Dade Behring BN II System, and correlation with creatinine. Clin Chem 2001, 47:2031-2033.
17. Newman D.J., Cystatin C. Ann Clin Biochem 2002, 39:89-104.
18. Seco M.L., Rus A., Sierra M., Caballero M., Borque L. Determination of serum cystatin C in patients with essential hypertension. Nephron 1999, 81:446-447.
19. Peralta C.A., Whooley M.A., Ix J.H., Shlipak M.G. Kidney function and systolic blood pressure new insights from Cystatin C: data from the Heart and Soul Study. Am J Hypertens 2006, 19:939-946.
20. Shi G.P., Sukhova G.K., Grubb A. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999, 104:1191-1197.
21. Morrow D.A., Sabatine M.S., Brennan M.L. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008, 29:1096-1102.
22. Sekizuka Hiromitsu, Akashi Yoshihiro J., Kawasaki Kensuke, Yamauchi Masahiro, Musha Haruki Cystatin C: a better marker to detect coronary artery sclerosis. Jpn Coll Cardiol 2009, 54:359-367.
23. Eriksson P., Jones K.G., Brown L.C., Greenhalgh R.M., Hamsten A., Powell J.T. Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms. Br J Surg 2004, 91:86-89.
24. Luc G., Bard J.M., Lesueur C., Arveiler D., Evans A., Amouyel P. Plasma cystatin-C and development or coronary heart disease: the PRIME study. J Atheroscler 2006, 185:37-80.
25. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodelling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262.
26. Koenig W., Twardella D., Brenner H., Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005, 51:321-327.
27. Kilic Teoman, Oner Gokhan, Ural Ertan, Yumuk Zeki, Sahin Tayfun, Bildirici Ulas, et al. Comparison of the long-term prognostic value of Cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. J Atheroscler 2009, 207:552-558.
28. Akerblom Axel, Wallentin Lars, Siegbahn Agneta, Becker Richard C., Budaj Andrzej, Steg Philippe Gabriel Cystatin C is an independent risk predictor for death or myocardial infarction in patients with ST elevation myocardial infarction (STEMI) as well as in non ST elevation acute coronary syndrome (NSTE-ACS). JACC 2011, 57:110-114.
29. Cerne D., Kaplan-Pavlovcic S., Kranjec I., Jurgens G. Mildly elevated serum creatinine concentration correlates with the extent of coronary atherosclerosis. Ren Fail 2000, 22:799-808.
30. Matts J.P., Karnegis J.N., Campos C.T. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract 1993, 36:497-503.
31. Tonelli M., Isles C., Curhan G.C. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004, 110:1557-1563.
32. Laterza O.F., Price C.P., Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem 2002, 48:699-707.
33. García Acuña José M., González-Babarro Eva, Grigorian Shamagian Lilian, Peña-Gil Carlos, Vidal Pérez Rafael, López-Lago Ana M., et al. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol 2009, 62:510-519.
34. Nicholls S.J., Tuzcu E.M., Crowe T. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol 2006, 47:1967-1975.
35. Moran A., Katz R., Smith N.L. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail 2008, 14:19-26.
36. Levin A., Cystatin C. Serum creatinine and estimates of kidney function: searching for better measures of kidney function and cardiovascular risk. Ann Intern Med 2005, 142:586-588.
37. Djoussé L., Kurth T., Gaziano J.M. Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 2008, 155:82-106.